EyePoint Pharmaceuticals Prepares for Investor Conferences
EyePoint Pharmaceuticals Prepares for Investor Conferences
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company devoted to developing and commercializing innovative therapeutics for patients suffering from serious retinal diseases, has announced its upcoming participation in several key investor conferences.
Upcoming Conferences
The company management will be attending the following notable events:
Morgan Stanley Annual Global Healthcare Conference
This conference will feature one-on-one investor meetings, allowing participants to engage directly with company representatives. The event is scheduled for an upcoming Wednesday.
Baird Global Healthcare Conference
EyePoint Pharmaceuticals will partake in a fireside chat at this conference, offering insights into the company's advances and future plans. This event is set for the coming Tuesday at 4:20 p.m. ET.
Cantor Global Healthcare Conference
During the fireside chat at this conference, EyePoint will further discuss its pipeline and product candidates. The event is planned for a Wednesday at 11:30 a.m. ET.
UBS Virtual Ophthalmology Day
This virtual event will also include a fireside chat with EyePoint Pharmaceuticals, scheduled for a Wednesday at 2:30 p.m. ET.
Webcast Availability
A live webcast and subsequent archived replay of the discussions can be accessed via the Investors section on the company's official website.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in treating serious retinal diseases through innovative methods. The company’s pipeline is anchored by its proprietary bioerodible Durasert E™ technology, which provides sustained intraocular drug delivery. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), represents a significant advancement in treating VEGF-mediated retinal diseases. This investigational drug combines vorolanib, a selective tyrosine kinase inhibitor, with Durasert E™ technology to provide sustained drug release.
Current Research and Development
DURAVYU is currently in Phase 2 clinical trials aimed at treating conditions such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which are leading causes of vision loss in the United States among older adults. EyePoint expects to commence pivotal Phase 3 trials for wet AMD soon.
Additional Pipeline Products
EyePoint’s pipeline includes EYP-2301, a promising TIE-2 agonist formulation aimed at enhancing outcomes for patients with serious retinal conditions. The Durasert® technology has been successfully deployed in four FDA-approved products, ensuring its efficacy and safety.
Licensing Agreements
Vorolanib, a key component in EyePoint's therapies, is exclusively licensed to the company from Equinox Sciences, part of the Betta Pharmaceuticals group, for treating localized ophthalmic diseases.
Contact Information for Investors and Media
For investor inquiries, please reach out to:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
For media inquiries, contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
Frequently Asked Questions
What is EyePoint Pharmaceuticals known for?
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases.
What are the key upcoming events for EyePoint Pharmaceuticals?
EyePoint is participating in several investor conferences, including events hosted by Morgan Stanley, Baird, Cantor, and UBS.
What is the lead product candidate of EyePoint Pharmaceuticals?
The lead product candidate is DURAVYU™, an investigational sustained delivery treatment for VEGF-mediated retinal diseases.
What technologies does EyePoint Pharmaceuticals utilize?
The company utilizes its proprietary bioerodible Durasert E™ technology to deliver drugs sustainably within the eye.
Where can I find more information about EyePoint Pharmaceuticals?
More information is available on the company's official website and during their upcoming investor presentations.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- The Nation Network Reveals Exciting Hockey Plans for 2024-25
- Glance at Canadian Stock Performance Amid Market Shifts
- Southline Project Gains Momentum for Enhanced Energy Infrastructure
- AGI's Pink Conveyor: A Charitable Initiative for Awareness
- Mirantis Lens Enhancements: A New Era for Kubernetes Management
- Kerecis Showcases Innovative Fish-Skin Technology for Wound Care
- Understanding the New Rating for abrdn Asia-Pacific Income Fund
- LendingClub Announces Conference Call for Q3 Earnings Release
- Summit Therapeutics Completes Enrollment for HARMONi Trial
- Solaris Energy Infrastructure Plans for COO Transition
Recent Articles
- Super Hi Reports Strong Q2 2024 Financial Results
- Invivyd's PEMGARDA™ Shows 84% Risk Reduction in COVID-19
- Supremex Launches First Environmental, Social and Governance Report
- Fox Factory's Commitment to Sustainability in 2023
- Clearside Biomedical Completes Final Participant Visit in ODYSSEY Trial
- Advancements in the Cosmetic Peptide Synthesis Market
- Vacuum Evaporation Boat Market Expected Growth to $4.1 Billion
- Skydance Media to Acquire Paramount Global Amid Bidding War
- Solar Coca-Cola Boosts Delivery Efficiency with Descartes
- Palo Alto Networks: AI and Cybersecurity Leadership
- Alliance Trust PLC Reports Latest Net Asset Value Insights
- Scotiabank Reports Drop in Q3 Profit Amid Credit Loss Provisions
- Iovance Biotherapeutics: A Path to Growth with Amtagvi
- Market Update: Investors Eye Nvidia's Earnings
- Aircraft Ground Support Equipment Market Growth Insights
- 3D Printing Glasses Market Growth Forecast
- Underground Mining Equipment Market Growth Forecast
- Laser Gas Analyzer Market Set to Reach $5.39 Billion by 2034
- Cheer Holding Secures Patent for AI Data Management System
- Parsons Announces Lead Engineering Role on Toll Lane Project
- Kronos Advanced Technologies to Acquire Suarez Corporation
- Disclosure of Interests by Rathbones Group Plc
- Key Disclosure by Rathbones Group Plc in Keywords Studios Plc
- Discover Wall Street's Top Dividend Stocks
- Top Stocks to Consider Ahead of Fed Rate Cuts
- Three AI Stocks Competing with Nvidia's Growth
- Epoxy Curing Agents Market Forecast to Reach USD 10.1 Billion
- Bitumen Market Projections: USD 116 Billion by 2034
- Toughened Glass Market Growth Forecast to Reach USD 94.6 Billion
- Calibre Enhances Gold Exploration Results at Pan Mine
- Jiayin Group Inc. Reports Strong Q2 2024 Financial Results
- Matrix Service Company Announces Fourth Quarter Financial Call
- Record High Household Debt in Canada: Insights and Implications
- LanzaTech's Upcoming Investor Events Engagement
- Liberty Bank, N.A. Opens New Branch in Millbrae Community
- JD.com Unveils $5 Billion Share Repurchase Initiative
- Elis Discloses Share Capital and Voting Rights Information
- Super Micro Computer's Growth Prospects Linked to Nvidia
- Electric Bike Kit Market Forecast: $2.9 Billion Growth
- Arachidonic Acid Market: Key Insights and Trends
- OKX Wallet Team Hosts Memecoin Insights Event on X Spaces
- Market Overview: Anticipating Nvidia Earnings and Economic Data
- Analysis of Fintech Stocks: PayPal, SoFi, and Block
- Automotive Ethernet Market Growth Predictions to 2032
- Global Brown Hydrogen Market Growth Insights
- Impact of ESG on Canadian Economy and Workers
- Acute Intermittent Porphyria Market Projected Growth Insights
- Aurora Mobile's JPush Solution and Huawei Partnership Insights
- GDS Holdings Limited Releases Comprehensive 2023 ESG Report
- Kvika Bank's Executive Committee and Board Changes